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What is known on this subject? 
Biomarkers that predict the clinical course of COVID-19 would be invaluable at the point of 
hospital admission. Several blood-based biomarkers have been suggested but have not been 
tested in a prospective UK cohort. 
 
What this study adds? 
In this prospective UK cohort, routinely performed blood biomarkers at the point of hospital 
admission had limited ability, in isolation, to predict poor outcomes from COVID-19. Biomarkers 








COVID-19 has an unpredictable clinical course so prognostic biomarkers would be invaluable 
when triaging patients on admission to hospital. Many biomarkers have been suggested using 
large observational datasets but sample timing is crucial to ensure prognostic relevance. The 
DISCOVER study prospectively recruited patients with COVID-19 admitted to a UK hospital and 
analysed a panel of putative prognostic biomarkers on the admission blood sample to identify 
markers of poor outcome. 
 
Methods: 
Consecutive patients admitted to hospital with proven or clinicoradiological suspected COVID-19 
were consented. Admission bloods were extracted from the clinical laboratory. A panel of 
biomarkers (IL-6, suPAR, KL-6, Troponin, Ferritin, LDH, BNP, Procalcitonin) were performed in 
addition to routinely performed markers (CRP, neutrophils, lymphocytes, neutrophil:lymphocyte 
ratio). Age, NEWS2, CURB-65 and radiographic severity score on initial chest radiograph were 
included as comparators.  All biomarkers were tested in logistic regression against a composite 
outcome of non-invasive ventilation, intensive care admission, or death, with Area Under the 
Curve (AUC) figures calculated. 
 
Results: 
187 patients had 28-day outcomes at the time of analysis. CRP (AUC 0.69 ,95%CI:0.59-0.78), 
lymphocyte count (AUC 0.62, 95%CI:0.53-0.72), and other routine markers did not predict the 
primary outcome. IL-6 (AUC: 0.77,0.65-0.88) and suPAR (AUC 0.81,CI: 0.72-0.88) showed some 
promise, but simple clinical features alone  such as NEWS2 score (AUC: 0.70 ,0.60-0.79) or age 




Admission blood biomarkers have only moderate predictive value for predicting COVID-19 
outcomes, while simple clinical features such as age and NEWS2 score outperform many 
biomarkers. IL-6 and suPAR had the best performance, and further studies should focus on the 






COVID-19 causes a wide spectrum of disease, from asymptomatic to severe respiratory failure. 
The majority of patients who present to hospital will recover but some develop rapidly progressive 
respiratory compromise requiring ventilatory support. Biomarkers that might predict this 
deterioration would be invaluable when triaging patients on hospital admission to inform who can 
be safely discharged versus those who need careful respiratory monitoring.  
  
The rapidly emerging literature base around biomarkers in COVID has mainly extracted data from 
electronic health records of large cohort studies. 1-4 Far fewer have prospectively recruited and 
followed up patients. Those that have tested novel biomarkers have often done so at later 
timepoints in patients limiting extrapolation to hospital admission.5-7 Few UK studies have 
assessed the additional value of biomarkers compared to the routinely recorded demographic 
information and clinical scales (such as National Early Warning Scores or CURB-65). 
  
The DIagnostic and Severity markers of COVID-19 to Enable Rapid triage (DISCOVER) study 
prospectively recruited patients admitted with COVID-19 to a single UK hospital, with the aim of 
comparing the ability of various biomarkers and clinical scores to predict mortality, need for non-













This was a prospective cohort study aimed to assess prognostic clinical and blood biomarkers for 




The primary outcome of prediction was a composite outcome of intensive care admission, non-
invasive ventilation (NIV) with Continuous Positive Airway Pressure (CPAP) or Bilevel Positive 
Airway Pressure (BIPAP) outside the intensive care unit, or death (defined below as “severe 
disease”). 
 




All patients were recruited via the DISCOVER study, a single centre observational study at North 
Bristol NHS Trust recruiting patients with COVID-19, from 30.03.2020 until 29.06.2020 (Ethics 
approval via South Yorks REC: 20/YH/0121, CRN approval no: 45469). Patients were recruited 
on the basis of a positive PCR result for SARS-CoV-2, using the established PHE assay in use 
at the time, or a clinicoradiological diagnosis of COVID-19 disease. During the pandemic, 
community testing became widely available, although the results were not available to hospital 
staff. As such, later patients were often recruited on the basis of a history of positive testing in the 
community. The only exclusion criteria was an inability to consent. For patients in intensive care, 







Clinical information was recorded on a REDCap (Vanderbilt University) database,8 by the 
consenting nurse or physician. Routine demographics were recorded, and presence of important 
comorbidities. Comorbidities were defined either by their recording in the admission notes / 
hospital record (for hypertension, heart disease, and chronic lung disease), the presence of a 
positive serological result (for HIV) or for requirement for dialysis or an estimated GFR of 
<30ml/min (for chronic kidney disease).  Ethnicity was also recorded. 
 
The earliest admission National Early Warning Score (NEWS2) was extracted from the clinical 
record. This is a numeric score (from 0-20), reflecting the degree of physiological dysfunction.9 
Higher numbers indicate more severe physiological dysfunction.. Routine biochemistry and 
haematology results were extracted from the clinical record, using the earliest available figure. 
Outcome data recorded was in line with RECOVERY, the national RCT of therapeutic 
interventions for COVID-19 (https://www.recoverytrial.net/). This included 28-day mortality, 
requirement for intensive care, ventilation, renal replacement therapy, and inotropes.  
 
Non-invasive ventilation was defined by the receipt of non-invasive ventilation by either 
continuous positive airway pressure (CPAP), bi-level positive airway pressure (BIPAP), or HFNO 
any time during the hospital stay. 
 
The radiological severity score was calculated using the method described by Wong et al, 2020.10 
A score of 0-4 was assigned to each lung depending on the extent of involvement by consolidation 
or ground glass opacities. 0 = no involvement, 1 = <25%, 2 = 25 - 49%, 3= 50 - 75%, 4 = >75% 
involvement. The scores for each lung were summed to produce a final severity score ranging 
from 0-8. Radiographs were scored by a respiratory and infectious diseases physician. 
 
Biomarkers and samples 
 
For conventional biomarkers of infection (namely C-reactive protein (CRP), components of the 
full blood count and routine renal function) data were prospectively recorded. The first result from 
that admission was taken or, for established inpatients, the result on the day of the diagnosis. 
These results were available to the clinician and therefore could impact on prognosis (i.e. 




 For other potential predictive markers (Lactate dehydrogenase (LDH), procalcitonin (PCT) 
interleukin-6 (IL-6), Krebs von den Lungen 6 (KL-6), Ferritin, Troponin, B-type natriuretic peptide 
(NT-pro BNP), soluble urokinase plasminogen activator receptor (suPAR)), analysis was 
performed on frozen samples in batch analysis as described below. Laboratory staff were 
unaware of clinical outcome and were therefore functionally blinded. 
 
The earliest initial sample was extracted from the blood sciences laboratory after routine testing 
had been performed; in admitted cases this was the initial sample taken in the Emergency 
Department (ED), in hospitalised cases, this was the sample from the day of diagnosis.  
 
suPAR analysis was performed on the suPARnostic® ELISA platform, KL-6 and Il-6 were 
performed on the Fujerebio Lumipulse. CRP, Ferritin, LDH, Troponin, NT-pro-BNP and 
Procalcitonin were performed on the Roche Diagnostics cobas platform. The specific analytic 
platforms were spectrophotometric: c701 (CRP) and c501 (LDH), immunoassay: e501 (Ferritin, 
Troponin, NT-pro-BNP, Procalcitonin). The full blood count was performed on the Sysmex XN 
(Sysmex Diagnostics). 
 
As the volume of blood required varied and was small, the total number of assays varied slightly 
as for some participants only enough blood was available to perform one or two assays, or there 




In this study, we aimed to identify whether any individual biomarker (Lymphocyte count, 
Neutrophil count,  Neutrophil:Lymphocyte ratio (NLR), CRP, IL-6, KL-6, suPAR, NT-pro BNP, 
LDH, PCT, Troponin T, Ferritin) had prognostic significance for the primary outcome as an 
individual marker, when used on the initial blood sample taken. 
 
There was a deliberate focus on relatively simplistic (logistic regression) models: given the sample 
size, complex models would be at risk of overfitting, and the main target was to identify the 
additional value of a biomarker, all of which are reported on a linear scale.11  Complete case 




ROC curves were generated, and AUC figures were calculated alongside sensitivity and 
specificity for each biomarker, at Youden’s index. Confidence intervals were generated around 
the AUC by bootstrapping. 
 
All analysis was performed in R (version 4.0.0), using the packages “tidyverse”, “broom”, 




Patient and Public Involvement 
Given the difficultly of performing PPI during a pandemic, patients were not involved in the design, 
or conduct, or reporting, or dissemination plans of the DISCOVER study at the time this 





187 participants had reached 28 days post diagnosis and were included in the analysis 
(prespecified timing of the primary outcome). Table 1 shows the demographics of the cohort. 101 
patients (54%) were male, and the median age was 58 (IQR: 46-73). 76% of the cohort had 
positive PCR results for SARS-CoV-2, with the remaining clinically suspected.  
 
Comorbidities were relatively common within the cohort with hypertension and diabetes being the 
most predominant. Patients with severe disease (death, intensive care admission or non-invasive 
ventilation) were generally older, and more comorbid than non-severe patients. 39 patients had 
the primary outcome. 15 patients went to the intensive care unit, of which 4 died and 11 survived. 




Table 1: Demographics of the study cohort.  
Characteristic Survivor,  
N = 148 
Non-survivor/ITU/NIV,  
N = 39 
p-
value2 
Age (18+) 55 (44, 71) 66 (60, 76) <0.001 
Sex   0.7 
Male 79 (53%) 22 (56%)  
Female 69 (47%) 17 (44%)  
PCR proven disease   0.6 
Proven 111 (75%) 31 (79%)  
Suspected 37 (25%) 8 (21%)  
Status at time of consent   0.010 
Inpatient 119 (80%) 38 (97%)  
Outpatient 29 (20%) 1 (2.6%)  
Diabetes status   0.3 
No 115 (78%) 34 (87%)  
T1DM 3 (2.0%) 1 (2.6%)  
T2DM 30 (20%) 4 (10%)  
Heart disease 34 (23%) 12 (31%) 0.3 
Chronic Lung disease 26 (18%) 20 (51%) <0.001 
Severe Liver disease 3 (2.0%) 2 (5.1%) 0.3 
Severe kidney impairment (eGFR< 30 
or dialysis) 
16 (11%) 6 (15%) 0.4 
Hypertension 37 (25%) 15 (38%) 0.10 
HIV status 1 (0.7%) 1 (2.6%) 0.4 
Non-white ethnicity 20 (16%) 5 (15%) 0.9 
Median (IQR); n (%) 
Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test 
 
There was a significant variation in physiological state (e.g. NEWS2), with a median NEWS2 
score of 4 (IQR 2-6), with the highest NEWS2 score recorded was 13. Patients that had severe 
disease had higher NEWS2 scores. There was also wide variation in functional status, with many 
patients having some degree of frailty, with frailer patients more likely to die or require enhanced 
care. Escalation status was recorded for most patients, with patients who died more likely to have 






Table 2: Escalation status 
 
Characteristic Survivor,  
N = 148 
Non-Survivor/ITU/NIV, 
N = 39 
For full escalation to ITU including 
intubation and ventilation 
104 (83%) 18 (55%) 
Not for invasive ventilation (intubation & 
ventilation) but would be for non-invasive 
ventilation (NIV) or CPAP on ward. 
8 (6.3%) 11 (33%) 
Not for ITU or for NIV/CPAP 14 (11%) 3 (9.1%) 
For palliative treatments only 0 (0%) 1 (3.0%) 
Unknown 22 6 
Statistics presented: n (%) 
 
Admission blood tests are recorded in Table 3. There was no significant difference for many blood 
tests, with lymphocyte count being slightly lower in those with severe disease, and 
neutrophil:lymphocyte ratio being slightly higher. Renal dysfunction was more common in the 











N = 148 
Non-Survivor/ITU/NIV,  
N = 39 p-value 
Haemoglobin (g/L) 135 (126, 148) 134 (112, 147) 0.4 
White cell count 
(x10^9/L) 7.6 (5.7, 9.9) 6.9 (5.0, 9.7) 0.7 
Neutrophils (x10^9/L) 5.7 (3.9, 8.0) 5.8 (3.7, 8.4) 0.6 
Lymphocytes (x10^9/L) 1.08 (0.68, 1.55) 0.86 (0.58, 1.16) 0.018 
Platelets (x10^9/L) 239 (189, 289) 202 (149, 258) 0.009 
Sodium (mmol/L) 138 (135, 140) 137 (136, 138) 0.4 
Urea (mmol/L) 4.7 (3.6, 7.1) 7.0 (5.0, 9.4) <0.001 
eGFR (ml/min) 89 (65, 90) 64 (50, 86) <0.001 
Albumin (mmol/L) 33.5 (31.0, 36.8) 32.0 (27.5, 34.0) 0.009 
CRP (mg/L) 44 (12, 86) 87 (54, 152) <0.001 
NLR 4.9 (2.8, 9.4) 6.3 (4.7, 12.3) 0.023 
1 Median (IQR) 
2 Wilcoxon rank sum test 
 
Logistic regression and AUC calculation 
 
Table 4 shows biomarker performance to predict severe COVID-19 outcomes.  Blood was not 
available for all participants for all tests, with the number included in each model listed.  Most 
biomarkers had modest predictive value, with suPAR (AUC 0.81) and IL-6 (AUC 0.77) having the 
best performance. Many biomarkers had weak performance (CRP, neutrophils, lymphocytes, KL-
6), with AUC figures between 0.5 and 0.65. ROC plots are available in the Supplemental Material 
















      
CRP (n = 179) 0.69 (0.59-0.78) 0.77 0.55 
Neutrophils (n = 185) 0.53 (0.43-0.64) 0.44 0.69 
Lymphocytes (n = 185) 0.62 (0.53-0.72) 0.85 0.38 
NLR (n = 185) 0.62 (0.53-0.71) 0.82 0.43 
IL-6 (n = 125) 0.77 (0.65-0.88) 0.70 0.83 
KL-6 (n = 149) 0.51 (0.38-0.65) 0.21 0.92 
suPAR (n = 150) 0.81 (0.72-0.88) 0.82 0.65 
Procalcitonin (n = 150) 0.72 (0.62-0.81) 0.94 0.43 
Ferritin  (n = 149) 0.64 (0.53-0.74) 0.59 0.69 
LDH (n = 149) 0.62 (0.51-0.72) 0.55 0.69 
Troponin (n=149) 0.70 (0.6-0.79) 0.88 0.45 
BNP (n=149) 0.64 (0.53-0.74) 0.67 0.58 
Age (n=187) 0.70 (0.62-0.77) 0.95 0.41 
NEWS2 score (n=182) 0.70 (0.60-0.79) 0.41 0.88 










Results of routine biomarkers (CRP, neutrophils, lymphocytes and NLR) are shown in Figure 2. 
Best performing novel biomarkers (IL-6, suPAR, LDH and PCT) box plots are shown in Figure 3 
(PCT values have been logged prior to plotting to aid visualisation as they had very wide ranges).  
 
Figure 2 – Boxplots of routine blood biomarkers 
 






For the composite outcome of ITU and mortality, results are reported in the supplementary 
Material. Due to a small number of events (18 deaths, 15 ITU admissions), confidence intervals 
were wider, but results were similar although perhaps slightly worse. Again, suPAR and IL-6 were 
the best performing biomarkers (AUC 0.81 for suPAR, AUC 0.70 for IL-6), with most other 






COVID-19 remains a clinical challenge. The majority of patients who present to hospital will 
recover but some develop rapidly progressive respiratory failure. Biomarkers that might predict 
this deterioration would be invaluable when triaging patients on hospital admission to inform who 
can be safely discharged versus those who might need intensive care support in the near future. 
This paper presents a prospectively recruited UK cohort of patients with COVID-19 with targeted 




A large observational study recruiting from the majority of NHS hospitals (ISARIC) estimates that, 
of the 34608 patients with outcome data, 7374 (17%) required admission to intensive care and 
11659 (33.7%) died within follow up.12 There have been numerous studies and meta-analyses on 
potential predictors of respiratory decline in COVID-19 pneumonia with the development of a 
‘cytokine storm’ in specific patients cited as a major determinant.13 14 As a result there has been 
a focus on biomarkers that rise in other similar conditions such as ferritin, lactate dehydrogenase 
(LDH), IL-6, and soluble urokinase plasminogen activator receptor (suPAR).15 A rise in 
cardiovascular events and coagulopathies has also been seen in patients with COVID-19 
pneumonia so biomarkers such as troponin, NT-pro BNP, fibrinogen and D-dimer have been 
studied.16-19 Given that mortality from COVID-19 increases with age and frailty, biomarkers of 
frailty have been shown to be related to worse outcomes (albumin, eGFR).2 12 20 Finally, given this 
is a respiratory infection, blood-based biomarkers that prognosticate bacterial pneumonia have 
been included in treatment guidelines and even entry criteria for clinical trials, including 




In this study, conventionally performed blood biomarkers, in isolation, did not predict outcome 
when performed on admission. Neutrophilia and C-reactive protein had AUC close to 0.5, with 
lymphopenia and NLR having only marginally better discriminative value. Cardiac markers were 
on average slightly higher in patients with worse clinical outcomes but should not be relied on to 
make treatment decisions at baseline. Literature suggests that they may have more utility when 




Markers of immune activation had more promise at the admission timepoint with IL-6 and suPAR 
the best-performing within this cohort. It has been hypothesized that an exaggerated immune 
response or ‘cytokine storm’ plays a significant role in COVID-19 and several therapies 
immunomodulatory therapies are being trialed.  IL-6 is a pro-inflammatory mediator for the 
induction of the acute phase response and shown to be a predictive marker of deterioration in 
other serious lung pathologies.  Specific to COVID-19, Han and colleagues assessed the cytokine 
profile of 102 patients, admitted to a single hospital in Wuhan, by disease severity on admission. 
From a panel of 6 cytokines (TNF-α, IFN-γ, IL-2, IL-4, IL-6 and IL-10), serum IL-6 was predictive 
of disease severity at the time with an AUC of 0.84, although longer term outcomes were not 
reported.22 Another prospective study of 89 patients admitted to a German hospital demonstrated 
that admission IL-6 was superior to other blood-based biomarkers at predicting the need for 
mechanical ventilation (using a cut-off of 35pg/ml). 22 Another prospective study of 89 patients 
admitted to a German hospital demonstrated that admission IL-6 was superior to other blood-
based biomarkers at predicting the need for mechanical ventilation (using a cut-off of 35pg/ml).6 
In our study, the admission IL-6 (at a cut-off of 74.9pg/ml) had a sensitivity of 0.70 and specificity 
of 0.84 (AUC 0.77). Randomised trial evidence is emerging showing treatment with the IL-6 
receptor antagonists, tocilizumab and sarilumab, improves outcomes, including survival in 
severely unwell patients with COVID-19.23  
 
suPAR, a marker of immune activation and has been shown to predict deterioration in several 
infectious and inflammatory disorders. It forms part of the fibrinolysis cascade and increased 
levels have been shown to pre-dispose to clotting abnormality and renal dysfunction, both of 
which are important drivers of morbidity and mortality in COVID-19. A prospective study of 57 
patients presenting with COVID-19 demonstrated that admission levels of suPAR were 
significantly greater among patients who eventually required ventilatory support.15 A cut-off of 
6ng/ml had a sensitivity of 86% and specificity of 92%. A prospective study of 57 patients 
presenting with COVID-19 demonstrated that admission levels of suPAR were significantly 
greater among patients who eventually required ventilatory support.15 A cut-off of 6ng/ml had a 
sensitivity of 86% and specificity of 92%. In our study it performed reasonably compared to other 
blood biomarkers but at a cut-off of 5.2ng/dl only had a sensitivity of 82% and specificity of 65%, 






The focus of this study was the additional role of blood biomarkers when initially assessing 
patients presenting with COVID-19. The DISCOVER cohort also collected routinely recorded 
clinical data including demographics, baseline observations and initial radiography.  It is notable 
that this easily accessible information outperformed many of the blood-based biomarkers tested.  
 
The National Early Warning Score (NEWS2) is used throughout the United Kingdom. There is 
currently limited evidence supporting its use in COVID-19.24 In China, Liao and colleagues created 
a non-validated COVID specific NEWS2 score (where age over 65 added 3 points).25 We could 
not find any prospective UK-based studies accessing the utility of NEWS2 in COVID-19 
admission. 25. In the DISCOVER cohort, NEWS2 score had an AUC of 0.70. The CURB-65 score 
is a severity scoring system for community acquired pneumonia and is often used to make 
decisions around need for hospital admission. Although previous retrospective literature from our 
centre has shown that CURB-65 scores are higher in patients with a worse outcome from COVID-
19,26 this prospective study has demonstrated that it cannot be relied upon to make treatment 




The DISCOVER cohort was prospectively designed and analysed the earliest emergency 
department blood sample, which is a key strength. Clinical meta-data was robustly recorded, and 
novel biomarkers were performed in batch assays, maximising replicability and reducing bias as 
results could not influence patient care.  Unlike other datasets (e.g. EHR extractions), we included 
patients who had clinically suspected COVID-19, as the currently available assays still have 
limited sensitivity.  Technicians were employed to extract blood out of auto-analyser machines to 
get the earliest possible sample, enabling recruitment of patients after admission or even as 
outpatients. Missing data around comorbidities was rare, as patients were prospectively recruited 




The major limitation of this study is the limited sample size, leading to imprecise estimates of 
biomarker performance.  A second limitation is the composite outcome of non-invasive ventilation, 
ITU admission and death which has been used in major interventional COVID-19 trials. Although 
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this is clinically useful and may aid differentiation of those who require specialist care, the 
provision and use of non-invasive ventilation is more clinician and hospital dependent and may 
be harder to extrapolate from. However, our secondary analysis of intensive care admission and 
death was largely similar, supporting this approach. Finally, although around 80% of patients had 
blood available, a proportion did not have excess sample available for additional testing, so only 
the routinely performed biomarkers (CRP, neutrophils, lymphocytes, neutrophil:lymphocyte ratio) 
are recorded for those patients. It is also important to note that these results were available to 
clinicians, and therefore may have biased the outcome (i.e. patients with high CRP may have 
received more aggressive therapy). At the time of recruitment to this study, there were however 




To our knowledge this is the largest recruited UK cohort of consecutive patients presenting with 
COVID-19. Blood biomarkers, when performed on admission bloods, had only moderate 
predictive value for COVID-19 similar to age and routine clinical scores (e.g. NEWS2 score). IL-
6 and suPAR had the best performance, and further, large prospective studies should validate 
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